Business Context and Reporting Period
Company: Propanc Health Group Corporation (also referred to as Propanc Biopharma, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2015
Event: Entry into a Material Definitive Agreement involving a securities purchase, convertible debenture issuance, and warrant grant.
Key Financial Metrics and Transaction Details
- Investment Amount: $4,000,000 total investment from Delafield Investments Limited.
- Convertible Debenture Principal: $4,400,000 (includes a 10% original issue discount).
- Warrants Issued: 26,190,476 shares at an exercise price of $0.60 per share, exercisable for 4 years.
- Debt Structure:
- Interest Rate: 5% per annum (payable quarterly in cash or stock).
- Maturity Date: October 28, 2016.
- Default Interest Rate: 18%.
- Escrow/Deposit Control: $2,800,000 of the investment is held in a deposit control account pending milestone and equity condition achievements.
- Prior Debt Cancellation: A prior promissory note of $1,200,000 was cancelled and included in the new investment amount.
- Security Interest: The Company granted a first-priority security interest in all assets to secure obligations until registration effectiveness and equity conditions are met.
Material Changes and Conversion Terms
The filing details a significant capital raise and debt restructuring. Key conversion and reduction terms include:
- Principal Reductions: The $4,400,000 principal amount is reduced by $25,000 if an SEC registration statement is filed within 30 days, and by an additional $25,000 if deemed effective within 100 days.
- Conversion Price:
- Standard: $0.042 per share (based on 5-day VWAP prior to execution).
- Discounted Conversion: If the VWAP is below the conversion price, the investor may convert at a 20% discount to the average of the two lowest closing prices in the prior 5 days.
- Default Conversion: Upon default, conversion is available at a 30% discount to the 3-day VWAP.
- Ownership Cap: Conversion is limited to prevent the investor from beneficially owning more than 4.99% of outstanding common stock.
- Redemption: The Company may redeem the debenture at 125% of the outstanding amount after 20 trading days of notice.
Guidance, Risks, and Contingencies
- Registration Rights: The Company must file a registration statement within 30 days and have it declared effective by the 100th day (subject to a 20-day extension) to cover the resale of shares underlying the debenture and warrants.
- Contingent Funding: A significant portion ($2.8M) of the capital is not immediately available for general use and is held in escrow pending specific milestones.
- Legal Costs: The Company agreed to pay up to $50,000 of the purchaser's legal fees.
- Exemption Status: The transaction was conducted under Section 4(a)(2) and Rule 506 of Regulation D, relying on the investor's status as an "accredited investor."
- Financial Statements: This 8-K does not provide revenue, profit, or cash flow data for the period; it focuses solely on the financing transaction.
Investor Verification Checklist
- Verify the status of the $2,800,000 held in the deposit control account and the specific milestones required for release.
- Confirm the filing and effectiveness date of the required SEC registration statement to determine if the $50,000 principal reduction applies.
- Assess the dilution impact of the 26,190,476 warrants and the potential conversion of the $4,400,000 debenture at the $0.042 conversion price.
- Review the Security Agreement to understand the scope of assets pledged as collateral.
- Check for any subsequent filings regarding the achievement of milestones or default events.